Prognostic value of cytokeratin 19 in hepatocellular carcinoma: A meta-analysis

Sun, Dawei; Zhang, Yingyi; Sun, Xu; Chen, Yuguo; Qiu, Wei; Ji, Min; Lv, Guoyue

doi:10.1016/j.cca.2015.06.027

Cited by 48 publications

(34 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, the combination of CK19 and GPC3 demonstrated better diagnostic sensitivity (90.6%) compared with the use of GP3 alone (54.2%) when applied for the detection of HCC in a study cohort of 518 patients 36. Consistently, several other studies also confirmed a correlation between increased CK19 expression and a lower survival rate and/or a shorter remission period in HCC patients 37,38. It is worth noting that CK19 expression was found to coincide with an increase in tumorigenic potential in preneoplastic hepatocytes,39 which could offer a mechanistic rationale for its use as a potential HCC biomarker.…”

Section: Review-biomarkers In Hccssupporting

confidence: 69%

Biomarkers for Hepatocellular Carcinoma

et al. 2017

View full text Add to dashboard Cite

show abstract

Section: Review-biomarkers In Hccssupporting

confidence: 69%

Biomarkers for Hepatocellular Carcinoma

et al. 2017

View full text Add to dashboard Cite

show abstract

“…All statistical tests were two-sided, and a P value less than 0.05 was deemed statistically significant. The statistical analyses, stratification analyses, and sensitivity analyses were the same as those used in our previous publications [15,21].…”

Section: Discussionmentioning

confidence: 99%

Albumin-fibrinogen ratio and fibrinogen-prealbumin ratio as promising prognostic markers for cancers: an updated meta-analysis

Sun

2020

World J Surg Onc

Self Cite

View full text Add to dashboard Cite

Objective: Provide an updated and comprehensive evaluation of the prognostic value of the albumin-fibrinogen ratio (AFR) and the fibrinogen-prealbumin ratio (FPR) for patients with cancer. Materials and methods: Four databases (PubMed, Web of Science, Cochrane Library, and WanFang) were searched. The primary endpoints were overall survival (OS), disease-free survival (DFS), and progression-free survival (PFS). Pooled data were synthesized using StataMP 14 and expressed as hazard ratios (HRs) and 95% confidence intervals (CIs). Results: This update examined 19 studies (7282 cases) that assessed the correlation of AFR with cancer prognosis. Pooled univariate and multivariate analyses indicated significant correlations of low AFR with poor OS (HR 2.18, 95%CI 1.87-2.55 and HR 1.75, 95%CI 1.54-2.00, respectively), poor DFS (HR 1.89, 95%CI 1.54-2.32 and HR 1.51, 95%CI 1.29-1.76, respectively), and poor PFS (HR 1.68, 95%CI 1.42-1.99 and HR 1.48, 95%CI 1.16-1.88, respectively). Pooled univariate and multivariate analyses of 6 studies (2232 cases) indicated high FPR significantly correlated with poor OS (HR 2.37, 95%CI 2.03-2.77 and HR 1.97, 95%CI 1.41-2.77, respectively). One study reported that high FPR correlated with poor DFS (univariate analysis: HR 2.20, 95%CI 1.35-3.57; multivariate analysis: HR 1.77, 95%CI 1.04-2.99) and one study reported a correlation of high FPR with poor PFS in univariate analysis alone (HR 1.79, 95%CI 1.11-2.88). Conclusion: A low AFR and a high FPR correlated with increased risk of cancer mortality and recurrence. AFR and FPR may be promising prognostic markers for cancers.

show abstract

“…While the HR and 95% CI were not directly reported in the studies, survival information was extracted from Kaplan-Meier curves and was used to estimate the HR. The log HR and SE were used to summarize the outcome of overall survival [ 40 ]. OR and their 95% CI were combined to assess the association between TUG1 expression and clinicopathological parameters, including DM, tumor size and tumor stage.…”

Section: Methodsmentioning

confidence: 99%

Long non-coding RNA TUG1 as a potential prognostic biomarker in human cancers: a meta-analysis

Guan

et al. 2017

Oncotarget

View full text Add to dashboard Cite

LncRNA taurine upregulated gene 1 (TUG1) is reportedly dysregulated in various cancers. We performed this meta-analysis to clarify the usefulness of TUG1 as a prognostic marker in malignant tumors. The PubMed, Medline, OVID, Cochrane Library, and Web of Science databases were searched from inception to Jan 11, 2017. Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated to explore the relationship between TUG1 expression and overall survival (OS). Odds ratios (ORs) were calculated to assess the association between TUG1 expression and pathological parameters. Thirteen original studies covering 1,274 cancer patients were included in this meta-analysis. The pooled HR suggested that high TUG1 expression correlated with poor OS (pooled HR=1.41, 95% CI: 1.01-1.98) in cancer types other than non-small cell lung cancer. TUG1 expression was also related to distant metastasis (OR=3.24, 95% CI: 1.18-8.93), large tumor size (OR=4.07, 95% CI: 1.08-15.28) and advanced tumor stage (OR=3.45, 95% CI: 2.19-5.44). Begg’s funnel plot and Egger’s test showed no evidence of obvious asymmetry for overall survival or tumor stage. Thus high TUG1 expression appears predictive of poor OS, distant metastasis, advanced tumor stage and large tumor size. This suggests TUG1 expression could serve as a biomarker for poor prognosis in cancers.

show abstract

Prognostic value of cytokeratin 19 in hepatocellular carcinoma: A meta-analysis

Cited by 48 publications

References 33 publications

Biomarkers for Hepatocellular Carcinoma

Biomarkers for Hepatocellular Carcinoma

Albumin-fibrinogen ratio and fibrinogen-prealbumin ratio as promising prognostic markers for cancers: an updated meta-analysis

Long non-coding RNA TUG1 as a potential prognostic biomarker in human cancers: a meta-analysis

Contact Info

Product

Resources

About